Michael Kollig’s Post

Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery - HIT Consultant Summary: Gilead Sciences and Genesis Therapeutics have joined forces to leverage AI in drug discovery, aiming to revolutionize the pharmaceutical industry. The partnership focuses on accelerating the development of innovative treatments through advanced technology and data analysis. Key areas of collaboration include AI algorithms, machine learning models, and predictive analytics to enhance drug discovery processes. This strategic alliance between Gilead and Genesis signifies a significant step towards integrating AI into healthcare research and development, paving the way for groundbreaking advancements in medicine. #Gilead #Genesis #AI #DrugDiscovery #HealthcareIT Headings: 1. Introduction to Gilead Sciences and Genesis Therapeutics Partnership #Gilead #Genesis #Partnership 2. Leveraging AI in Drug Discovery #AI ai.mediformatica.com #gilead #collaboration #platform #aiplatform #drugdevelopment #advanced #biopharmaceutical #drugdiscovery #edge #partnership #strategic #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3XlCXlW)

Isomorphic Labs to Collaborate with Eli Lilly and Company and Novartis Isomorphic Labs announced strategic #collaborations with leading #pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly €2.75 billion ($3 billion) to Isomorphic Labs, excluding any royalties that may result from future drug sales. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments. The Eli Lilly partnership is set to discover small molecule #therapeutics against multiple targets. Isomorphic Labs will receive an upfront cash payment of €41 million ($45 million) and are eligible for up to €1.55 billion ($1.7 billion) in performance-based milestone payments, excluding royalties on net sales. "We’re thrilled to embark on this partnership and apply our proprietary #technology platform, the next generation of AlphaFold, and access to massive computing power to Lilly's development programs,” said Demis Hassabis, CEO and founder of Isomorphic Labs. Read more on #CMI online: https://lnkd.in/ePa5dtid

Happy to share that Insilico Medicine and invoX Pharma - a research-driven global biopharma company - have announced a new strategic partnership to boost InvoX Pharma's anti-cancer pipeline for potential indications expansion. The collaboration is set to leverage Insilico's expertise in AI drug discovery, as well as InvoX's experience in drug development and data science. Specifically, the partnership will use Insilico's independently-developed target discovery engine, PandaOmics®, in combination with InvoX's internal drug development team's experience. This partnership aims to analyze existing InvoX pipelines to identify new potential indications, and further assess the feasibility of candidate drugs for potential indication treatments. #QMportfolio #QMhealthcare #insilicomedicine #InvoXPharma #StrageticPartnership #DrugDiscovery #AI #PandaOmics #CancerResearch #Biopharmaceuticals #DataScience

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease. So what's next? They expect to begin enrolling Huntington's patients, who presently have few therapeutic options and none that reverse or slow disease progression. SKY-0515 has demonstrated strong activity in preclinical models which is believed will translate to patient benefit. What do you think of this news? #lifesciences #menloparklifesciences #pharmaceutical #pharma #science #skyhawk #SKY-0515

Exciting times in the world of innovative ADCs! Check out Differentia's Integrative ADC platform for drug discovery and development, as highlighted by CEO Kas Subramanian and others in a recent publication by Scheuher, Ghusinga, McGirr, et al. "Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)." J Pharmacokinet Pharmacodyn (2023) Differentia's ADC platform offers a range of capabilities, including identifying optimal target combinations for bispecific ADCs, estimating antibody properties, selecting payloads, and predicting doses for First-in-Human studies. It also supports various regulatory submissions like INDs, NDAs, and BLAs. This platform, calibrated against two HER2 targeting ADCs, T-DM1 and T-DXd, leverages preclinical data to aid in making clinical predictions. Notably, it can be tailored to represent any other ADC, making it a versatile tool for drug development. Learn more about recent innovative ADC approaches here: [Link to the article] #ADCs #DrugDiscovery #PharmaInnovation #ClinicalPredictions

Hello connections I've completed the Drug development process: combating pain course! Here's what I learned - Understanding pain clinical and preclinical Evaluations - Drug discovery process a- Opioid drugs b- Steroid drugs C-NSAIDS - Conclusion In this course you have had a brief introduction to how the drug-discovery process is conceived and initiated. You should by now have some appreciation of the intrinsic difficulties associated with developing a drug molecule from conception into a medicine suitable for clinical use and of how molecular modelling can be used in the drug discovery process. - Excited to apply these new skill in Healthcare. #drugdevelopment #drugdiscovery #pharmaceuticals

How do you reduce the number of samples required for cell therapy release assays, when we have low yield of drug product itself? Join Jigesha Dholakia for her roundtable discussion on the topic at our Advanced Therapies Roundtable Xchange happening in #SanDiego, February 29th 2024. To view all facilitators, agendas, registration info and more, please visit: https://lnkd.in/eQAUQU7Y Note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #manufacturing #therapeutics #therapies #oligonucleotide #genetherapies

🔎 Have ONO PHARMACEUTICAL CO., LTD. found the next best target? 🤝 Last week we saw Ono Pharmaceutical combine forces with LigaChem Biosciences in a deal of up to $700 million, driving progress of first-in-class solid tumour candidate LCB97. 📈 This exciting release has caught the eye of many, opening the door to a potential new avenue of ADC targets, with LCB97 being the first of it’s kind targeting cells expressing L1CAM. Is this new ADC target destined for clinical success? 💡 In a congested ADC field, the ever-growing landscape of biopharma and biotech are now allocating significant resources into selecting novel targets for ADCs, adopting a first-in-class approach to development, embarking on a mission to find that golden nugget to break through the noise in this booming field. 🎫 The 4th ADC Target Selection Summit is uniquely positioned at the home of such discussion, fostering discussion around both strategic and technical considerations when identifying and validating novel targets which can be efficacious in ADC drug delivery. 📜 View the full agenda for the summit here – https://ter.li/6jkh9q 💫 Join Oxford BioTherapeutics, AbbVie, Bristol Myers Squibb, GO Therapeutics and many more who will be touching down in San Diego this December to outline target selection strategy, including discussion around artificial intelligence, bispecific targets, expression dynamics and more. 📥 If you have any questions at all regarding the summit, please do not hesitate to reach out, my inbox is always open! #adc #antibody #drug #conjugate #target #novel Iwan Cleave Ella Broome Karim Hoceine

Isomorphic Labs has announced collaborations with pharmaceutical giants Eli Lilly and Novartis for AI-driven drug discovery. The partnerships aim to leverage Isomorphic Labs' expertise in artificial intelligence to enhance the drug discovery process. The article provides insights into the potential impact of these collaborations on advancing innovative drug development through the integration of cutting-edge technologies. #machinelearning #artificialintelligence #drugdiscovery #pharmaceutical #drugdevelopment #smallmolecule #computationalchemistry #structuralbiology

Hello connections I've completed the Drug development process: combating pain course!🚀 Here's what I learned📌 - Understanding pain - clinical and preclinical Evaluations - Drug discovery process a- Opioid drugs b- Steroid drugs C- NSAIDS - Conclusion In this course you have had a brief introduction to how the drug-discovery process is conceived and initiated. You should by now have some appreciation of the intrinsic difficulties associated with developing a drug molecule from conception into a medicine suitable for clinical use and of how molecular modelling can be used in the drug discovery process. - Excited to apply these new skill in Healthcare. #drugdevelopment #drugdiscovery #pharmaceuticals